Innovations in coagulation: improved options for treatment of hemophilia A and B.
作者信息
Pabinger-Fasching Ingrid, Pipe Steven
出版信息
Thromb Res. 2013 Mar;131 Suppl 2:S1. doi: 10.1016/S0049-3848(13)00051-0.
Abstract
摘要
相似文献
1
Innovations in coagulation: improved options for treatment of hemophilia A and B.凝血领域的创新：治疗甲型和乙型血友病的改良选择。
Thromb Res. 2013 Mar;131 Suppl 2:S1. doi: 10.1016/S0049-3848(13)00051-0.
2
Plasma derivatives: new products and new approaches.血浆衍生物：新产品与新方法。
Biologicals. 2012 May;40(3):191-5. doi: 10.1016/j.biologicals.2011.11.003. Epub 2012 Jan 11.
3
[Substitution therapy of hemorrhagic diseases].[出血性疾病的替代疗法]
Anasthesiol Intensivmed Prax. 1975 Oct;11(1):137-44.
4
Surgery in haemophilic patients with inhibitors.伴有抑制物的血友病患者的手术治疗
Haemophilia. 2004 Sep;10 Suppl 2:1-2. doi: 10.1111/j.1365-2516.2004.00933.x.
5
6
[Pharmacotherapy of hemophilia with the preparation of Lagochilus inebrians BGE].
Folia Haematol Int Mag Klin Morphol Blutforsch. 1971;95(1):72-83.
7
Estimating and interpreting the pharmacokinetic profiles of individual patients with hemophilia A or B using a population pharmacokinetic approach: communication from the SSC of the ISTH.采用群体药代动力学方法评估和解读甲型或乙型血友病个体患者的药代动力学特征：国际血栓与止血学会科学和标准化委员会的通讯
J Thromb Haemost. 2017 Dec;15(12):2461-2465. doi: 10.1111/jth.13867. Epub 2017 Nov 9.
8
Innovative coagulation factors: albumin fusion technology and recombinant single-chain factor VIII.创新的凝血因子：白蛋白融合技术和重组单链因子 VIII。
Thromb Res. 2013 Mar;131 Suppl 2:S2-6. doi: 10.1016/S0049-3848(13)70150-6.
9
Improved coagulation in bleeding disorders by Non-Anticoagulant Sulfated Polysaccharides (NASP).非抗凝硫酸多糖（NASP）改善出血性疾病中的凝血功能。
Thromb Haemost. 2006 Jan;95(1):68-76.
10
The evolution of recombinant factor replacement for hemophilia.血友病重组因子替代疗法的演变
Transfus Apher Sci. 2019 Oct;58(5):596-600. doi: 10.1016/j.transci.2019.08.010. Epub 2019 Aug 9.
Zotero 插件